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Age at first birth in women is 
genetically associated with 
increased risk of schizophrenia
Guiyan Ni1,2, Jacob Gratten3,4, Schizophrenia Working Group of the Psychiatric Genomics 
Consortium*, Naomi R. Wray  3,4 & Sang Hong Lee1,2,4
Previous studies have shown an increased risk for mental health problems in children born to both 
younger and older parents compared to children of average-aged parents. We previously used a novel 
design to reveal a latent mechanism of genetic association between schizophrenia and age at first 
birth in women (AFB). Here, we use independent data from the UK Biobank (N = 38,892) to replicate 
the finding of an association between predicted genetic risk of schizophrenia and AFB in women, and 
to estimate the genetic correlation between schizophrenia and AFB in women stratified into younger 
and older groups. We find evidence for an association between predicted genetic risk of schizophrenia 
and AFB in women (P-value = 1.12E-05), and we show genetic heterogeneity between younger and 
older AFB groups (P-value = 3.45E-03). The genetic correlation between schizophrenia and AFB in 
the younger AFB group is −0.16 (SE = 0.04) while that between schizophrenia and AFB in the older 
AFB group is 0.14 (SE = 0.08). Our results suggest that early, and perhaps also late, age at first birth 
in women is associated with increased genetic risk for schizophrenia in the UK Biobank sample. These 
findings contribute new insights into factors contributing to the complex bio-social risk architecture 
underpinning the association between parental age and offspring mental health.
An increased risk for a range of mental health issues in children born to both younger and older parents com-
pared to children of average-aged parents has been reported in many studies1–8, with a particular focus on the risk 
of schizophrenia (SCZ) in children associated with parental age9–12. A recent comprehensive analysis using family 
data extracted from the Danish Psychiatric Central Register reported a relationship between mother’s age and 
risk of SCZ in her offspring13. They showed that there was higher risk in children of younger and older mothers 
compared to those of intermediate age (25–29 years – i.e. a U-shaped relationship between maternal age and risk 
of SCZ in offspring), but it was unclear if this was due to psychosocial factors associated with maternal age or if 
mothers at higher genetic risk for SCZ tend to have children at an earlier or later age. Moreover, the very high 
correlation in spousal ages makes paternal and maternal contributions to this relationship difficult to disentan-
gle. A number of possible latent mechanisms behind these epidemiological observations have been proposed14, 
including shared genetic risk factors between parents and offspring15,16 (Fig. 1). A better understanding of factors 
contributing to the relationship between parental age and risk of psychiatric disorders is important for informing 
any future public health initiatives targeting this relationship.
We have previously reported evidence for a genetic relationship between maternal age at first birth (AFB) 
and risk of SCZ17, as illustrated in red in Fig. 1. We employed a novel design that directly tests the genetic risk 
of SCZ in mothers depending on AFB. In all previous study designs the psychiatric disorder was measured in 
the child, and hence the relationship with AFB in the mother was confounded with characteristics of the father. 
Here, and in our previous study we examine the relationship between SCZ and AFB by using a genetic predictor 
of SCZ in the mother. The analyses use community samples of women enrolled in research studies that were not 
enriched for psychiatric disorders (<1% for diagnosis with SCZ). The genetic predictor for SCZ can be calculated 
for all women in the studies as a function (such as weighted sum) of the SCZ risk alleles they carry, with the risk 
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alleles identified as having increased frequencies in SCZ cases compared to controls. A woman’s genetic risk for 
schizophrenia is solely a function of her DNA, which she received independently of the characteristics of her 
partner. Hence, a benefit of this novel design is that the inferred association is not confounded by artefactual or 
non-genetic association(s) such as increased SCZ risk in offspring due to maternal environmental effects or by 
confounding with father’s age. We showed that the U-shaped relationship (between maternal age at birth and SCZ 
risk in offspring) observed in epidemiological studies was also observed when considering predicted genetic risk 
for SCZ as a function of AFB in healthy women13,17.
In this study, we replicate and extend our earlier findings17 using the UK Biobank data in which community 
samples of women have been measured for AFB. First, we confirm that SCZ polygenic risk score (PRS) for women 
in the UK Biobank with a record of AFB (N = 38,892) significantly predicts the U-shaped relationship found in 
McGrath et al.13, thereby replicating the results in Mehta et al.17. Second, we test if there is a genetic heterogeneity 
for AFB between younger and older AFB groups. Third, we estimate the genetic correlation between SCZ and 
AFB in younger and older AFB groups.
Results
Overview. In total, 41,630 SCZ GWAS samples including 18,957 cases and 22,673 controls from 30 cohorts 
were used in this study (Table S1), which were the same data used in Mehta et al.17. For the UK Biobank sample, 
38,892 women were used. The distribution of AFB, age at interview, and year of birth for the UK Biobank data 
after QC are shown in Fig. S1. In total, 518,992 SNPs passed the quality control criteria and were in common 
across the SCZ and UK Biobank samples. The distribution of MAF is shown in Fig. S2. Figure S3 shows that there 
were no closely related individuals in the UK Biobank and SCZ case-control data sets, confirming that the two 
data sets were independent.
We estimated SCZ PRS for each individual in the UK Biobank sample, using the SCZ GWAS as a reference 
data set (see Methods). We used both the genetic profile score approach18 (PRS-score) and genomic best linear 
unbiased prediction method (PRS-GBLUP). We assessed the U-shaped relationship between AFB and SCZ PRS 
for the UK Biobank sample. We emphasize that in this novel design, it was not necessary to measure SCZ risk in 
offspring, and in our strategy potential confounding due to a correlation between paternal and maternal age was 
mostly removed.
Subsequently, we estimated SNP-heritability and genetic correlation between AFB and SCZ. Because of the 
non-linear relationship (U-shape), we divided the UK Biobank sample into two groups with younger and older 
AFB. We assessed if the younger and older AFB groups were genetically heterogeneous, and if there is any signif-
icant genetic correlation between SCZ and each of the younger and older AFB groups.
Relationship between SCZ PRS and AFB. Consistent with McGrath et al.13 and replicating the findings 
in Mehta et al.17, a U-shaped relationship was observed between AFB and SCZ PRS-GBLUP (Fig. 2 and Table S2), 
implying genetic pleiotropic effects on AFB and SCZ risk. Figure 2 shows the mean and standard error of SCZ 
PRS-GBLUP in the UK Biobank sample grouped by AFB. The mean SCZ PRS-GBLUP in women with early AFB 
(<20 years) was significantly higher than that in women with intermediate AFB (P-value = 2.2E-02 for AFB 
between 20 to <25 years, P-value = 1.2E-05 for AFB between 25 to <30 years, P-value = 2.0E-02 for AFB between 
30 to <35 years, in Table S3), but not in women with high AFB (P-value = 4.9E-01 for AFB ≥ 35 years). The mean 
SCZ PRS-GBLUP in women with AFB between 25 to <30 years was significantly lower than that in women with 
AFB between 20 to <25 years (P-value = 2.0E-03). Our results confirmed the findings in Mehta et al.17, i.e. a 
U-shaped relationship between AFB and SCZ PRS attributed to latent genetic factors, with stronger significance. 
The results were similar whether PRS was calculated using GBLUP (PRS-GBLUP) or conventional profile scoring 
based on GWAS summary statistics from the SCZ GWAS data (PRS-score) (Fig. S4 and Table S3). We also con-
firmed that the U-shaped relationship was replicated with estimated SNP effects from the full PGC SCZ GWAS 
Figure 1. A flowchart of suggested mechanisms contributing to the relationship between the parental age and 
the schizophrenia risk in offspring.
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study (PRS-scorePGC) (See Fig. S4 and Table S4), although these results could be biased due to possible sample 
overlap or the presence of relatives between the UK Biobank and the full PGC SCZ data.
Linear predictor. Following Mehta et al.17, we tested if SCZ PRS could predict the response variable (see 
Methods) that described the relationship between SCZ risk in offspring and maternal age derived in McGrath et al.13. 
Figure 3 shows that the response variable was significantly predicted by SCZ PRS for the group with the full range 
of AFB (P-value = 1.12E-05 for PRS-GBLUP, and P-value = 3.53E-07 for PRS-score and P-value = 3.08E-06 for 
PRS-scorePGC) and the subgroup with AFB younger than 26 (P-value = 4.71E-06, 6.06E-08 and 2.45E-06 for 
PRS-GBLUP, PRS-score and PRS-scorePGC, respectively), but not for the subgroup with AFB older than 26. 
The prediction with PRS-score was stronger than that with PRS-scorePGC, and both stronger than that with 
PRS-GBLUP although the results across the methods were not substantially different (Fig. 3).
Education level, income level, smoking and alcohol drinker status were additionally used to adjust the 
response variable in the linear prediction to test if those factors diminish the signals. Even with this conservative 
model, our results for the group with full range of AFB and the subgroup with AFB younger than 26 remained 
significant (Fig. S5 and Table S5), albeit with reduced effect size and significance. The reduced significance might 
be partly explained by the reduced sample size (i.e. for full range of AFB, N = 38,892 in the base model and 31,848 
Figure 2. Mean and standard error of schizophrenia polygenic risk scores estimated from Genomic Best Linear 
Unbiased Prediction (GBLUP) in the UK Biobank sample grouped by age at first birth.
Figure 3. −log(P) values for the null hypothesis of R2 = 0 based on the linear prediction. Full range of AFB: 
All available samples with a record of age at first birth were used. AFB < 26 (≥26): Analyses were only focus 
on samples with AFB < 26 (≥26). PRS-GBLUP: Schizophrenia (SCZ) polygenic risk scores estimated from 
genomic best linear unbiased prediction were used as an explanatory variable in the model. PRS-score: SCZ 
polygenic risk scores estimated from genome-wide association study based on available individual genotype 
data were used as an explanatory variable in the model. PRS-scorePGC: SCZ polygenic risk scores estimated 
from summary statistics results of full PGC SCZ GWAS study were used as an explanatory variable in the 
model. Response variables were generated with a polynomial function derived by Mehta et al.17, which describes 
the relationship between SCZ risk in offspring and maternal age (z = 2.7214 − 0.1105X + 0.0018X2, where X is 
age at first birth), and used in the model in which the AFB phenotypes were adjusted for age at interview, year of 
birth, assessment center at which participant consented, genotype batch, and the first 20 principal components.
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in model adjusted for education and income; see Table S5). In sensitivity analyses we also restricted the sample to 
those recruited at age ≥45 years (N = 35,451), which included the vast majority of women with a record of AFB, 
so that results were not biased by the exclusion of women with no reported AFB measure. We found that there 
was no substantive difference in our results despite the reduced sample size (Table S5 vs. S6).
The UK Biobank sample was divided into two subgroups born before or after 1945, a boundary of post-
ponement of AFB based on the theory of the second democratic transition19. For individuals born after 1945, 
PRS-GBLUP significantly predicted the response variable for the group with the full range of AFB and the sub-
group with AFB younger than 26, even after adjusting for socioeconomic status, and smoking and alcohol drinker 
status, but not for the subgroup with older AFB. For individuals born before 1945, PRS-GBLUP did not sig-
nificantly predict the response variable for the group with the full range of AFB (P-value = 6.52E-02) nor the 
subgroup with AFB younger or older than 26 (P-value = 4.99E-02 or 4.38E-01) (Table S7). Our results agreed 
with the results of Mehta et al.17 in that SCZ PRS of women significantly predicted the response variable for the 
group with the full range of AFB and the subgroup with AFB younger than 26. The signals became stronger for 
the individuals born after year 1945.
Genetic correlation between AFB and SCZ. Given that the AFB for women in the UK Biobank data was 
significantly predicted by PRS-GBLUP (P-value = 1.12E-05 and R2 = 4.96E-04 in Table S5), it was of interest to 
estimate the genetic correlation between AFB and SCZ, which is the scaled proportion of variance that AFB and 
SCZ share due to genetic factors.
The SNP-heritability was 0.03 (SE = 0.01), 0.10 (SE = 0.01), and 0.20 (SE = 0.004), for older AFB, younger 
AFB, and SCZ, respectively. The SNP-heritability for the older AFB group was not significantly different from 0 
(Fig. 4 right panel).
The estimated genetic correlation between younger and older AFB groups was significantly less than 1 
(rg = 0.47, SE = 0.19, P-value = 3.45E-03, in Table S8), indicating that younger and older AFB were genetically 
heterogeneous in the UK Biobank (Fig. 4 left panel). We demonstrate that a truncated selection had little impact 
on the estimation of the genetic correlation20 (Supplemental Notes 1 and 2 and Figs S6 and S7). Further, the 
estimated genetic correlation between SCZ and AFB in the younger AFB group was −0.16 (SE = 0.04) and that 
between SCZ and AFB in the older AFB group was 0.14 (SE = 0.08) (Fig. 4 left panel).
In sensitivity analyses, education level, income level, smoking and alcohol drinker status were additionally 
used to adjust the phenotypes in the genomic residual maximum likelihood (GREML) analyses to see if those fac-
tors change the estimates. Figure S8 shows that the estimates and their significance were slightly reduced, which 
could be partly explained by the decrease of sample size (N = 38,892 in the base model versus 31,848 in the model 
adjusted for education and income; see Table S8).
In addition to GREML, linkage disequilibrium score regression (LDSC)4,21 was applied to estimate the genetic 
correlation between SCZ and younger and older AFB (Table S9). As recommended by the LDSC papers4,21, 
pre-estimated LD scores from the 1000 Genome reference sample without constraining the intercept of regres-
sion were applied to the QCed GWAS data and full PGC SCZ GWAS summary results. However, we could access 
individual genotype data and it was clearly known that there was no overlapping sample and no high relatedness 
in the QCed GWAS data for which we would be able to use LD scores estimated based on the actual genotype 
Figure 4. Genetic correlation (left) and heritability (right) of age at first birth (AFB) ≥ 26, AFB < 26, and 
schizophrenia (SCZ). Cor(AFB < 26, AFB ≥ 26): Estimated genetic correlation between the groups with 
AFB < 26 and with AFB ≥ 26. Cor(SCZ, AFB ≥ 26): Estimated genetic correlation between SCZ and AFB in the 
older AFB group. Cor(SCZ, AFB < 26): Estimated genetic correlation between SCZ and AFB in the younger 
AFB group. The bars are standard errors. In the model, the AFB phenotypes were adjusted for age at interview, 
year of birth, assessment center at which participant consented, genotype batch and the first 20 principal 
components. And the SCZ phenotypes were adjusted for sex, cohorts and the first 20 principal components. The 
sample size for group AFB ≥ 26 was 17,598 and for group AFB < 26 was 21,294, and for group SCZ was 41,630.
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data as well as to constrain the intercept as zero. As reported4,21, it was observed from simulations (Supplemental 
Note 3) that if there was no overlapping sample, LDSC with constraining the intercept as zero gave the most accu-
rate estimate with the least standard error (Fig. S9). In the real data analyses, Table S9 showed that LDSC with 
constraining the intercept as zero gave similar estimates and standard errors, compared to those from GREML 
when using the QCed data. When explicitly estimating the intercept, the standard errors became large; therefore 
the precision of estimates might be decreased (Table S9). When using the full PGC SCZ GWAS summary, LDSC 
gave similar estimates but larger standard errors, compared to GREML estimates, although a larger SCZ sample 
size was used for LDSC analyses (77,096 for LDSC vs. 41,630 for GREML).
Discussion
Parental age has been consistently associated with an increased risk of SCZ in offspring9–13,15,16,22,23, but it is well 
known that traditional epidemiological study designs, based on data measured for parental age and SCZ status 
in their offspring, have limitations with respect to disentangling genetic effects from non-genetic confounding 
effects such as common and residual environmental effects (Fig. 1). The elevated risk of SCZ associated with 
parental age extends to children of both younger and older parents, compared to children of average aged par-
ents – i.e. a U-shaped relationship13. The most widely accepted mechanism, in the case of delayed parenthood, 
is a causal relationship due to the accumulation of de novo mutations with age (e.g. Kong et al.24), although this 
cannot explain increased risk in offspring of younger parents. This hypothesis is biologically plausible25–28, but 
Gratten et al.29 have shown using theory and simulations that paternal age-related de novo mutations are unlikely 
to be the major causal factor responsible for increased risk of SCZ in offspring. Instead, they argued that increased 
risk of SCZ in offspring of older fathers could be due to genetic overlap between risk of SCZ and delayed parent-
hood. This finding is consistent with epidemiological studies showing that paternal age at first child, as opposed 
to paternal age at conception, accounts for the increased risk of SCZ in the children of older fathers (i.e. arguing 
against a direct causal role for age-related de novo mutations)15,16. Notably, this mechanism of genetic overlap 
between parental age and SCZ applies equally well to offspring SCZ risk associated with early parenthood.
Recently, Mehta et al.17 used a novel design to investigate the genetic relationship between SCZ and AFB in 
women that is free of many of the potential confounders present in epidemiological study designs (e.g. poor 
maternity skill, psychosocial factors and shared environmental factors). Specifically, they used SNP effects 
obtained using SCZ case-control data to estimate genetic risk of SCZ in a general community sample of women 
measured for AFB. As expected, psychiatric disorder including SCZ was not enriched in this community sample 
(i.e. a general population). Therefore, there is hardly phenotypic assortative mating for the psychiatric disorder 
in the sample. In addition, the analyses were restricted to individuals with pairwise genomic relationship <0.05 
across samples to make sure that SCZ GWAS and AFB samples were independent. Thus, it was unlikely that they 
shared the common environmental factors. In this analysis, we used the novel design and replicated the finding 
in a much larger and independent community sample, the UK Biobank study. We confirmed the U-shaped rela-
tionship between AFB and SCZ PRS reported by Mehta et al.17 (Figs 2 and 3), and provided evidence of genetic 
overlap between SCZ and AFB in women. The large number of samples in the UK Biobank made it possible to 
also estimate genetic variance and covariance between SCZ and AFB using a linear mixed model, showing that 
the traits of younger and older AFB are genetically heterogeneous (Fig. 4 or Table S8). The genetic correlation 
between SCZ and AFB in women with AFB < 26 was −0.16 (SE = 0.04), which was significantly different from 
zero (Fig. 4). The genetic correlation between SCZ and AFB in women with AFB ≥ 26 was 0.14 (SE = 0.08), which 
was significantly larger, albeit by a marginal amount, than zero in a one-tail Wald test (p-value = 0.04). This shows 
that there is at least a suggestive signal for the genetic correlation between older AFB and SCZ, hence we cannot 
totally rule out the possibility of the association.
In linear prediction, results from PRS-score were similar to or more significant than those from PRS-scorePGC 
(Table S5). This is noteworthy because PRS-scorePGC was based on the GWAS summary statistics from the full 
PGC SCZ GWAS (33,640 cases, 43,456 controls, from 52 cohorts), which is a larger sample than that used to 
generate PRS-score (individual-level genotype data on 18,957 cases, 22,673 controls, from 30 cohorts). However, 
publicly available GWAS summary statistics such as those used for PRS-scorePGC provide incomplete informa-
tion about sample overlap or pairwise relationships between data sets, either of which could introduce biases or 
influence statistical significance due to non-independence of samples. There is an approach or strategy for related-
ness QC without accessing individual genotypes30, however, it is not immediately applicable to the full PGC SCZ 
data. We hypothesize that the superior performance of PRS-score in our analysis, despite smaller sample size than 
PRS-scorePGC (which is explained by restrictions on data access for individual-level genotype data), reflects the 
very stringent QC we applied to the data, including on relatedness.
In this study, we could not test the significance of association between SCZ PRS and SCZ status for the UK 
Biobank sample because there was no information about SCZ outcome for the sample. However, we conducted 
an association test between the SCZ PRS and bipolar disorder (that is highly correlated with SCZ) for the UK 
Biobank (P-value = 1.02E-08 with 4,508 bipolar cases and 8,821 controls). This showed that the SCZ PRS was 
a reliable predictor of the true underlying SCZ liability for the UK Biobank sample. We also did not adjust for 
the assortative mating effects because the partner information is not available. However, it is not likely that such 
genetic assortative mating effects are substantial although a further study is required to test this hypothesis.
Estimated genetic correlations and their standard errors based on GREML and LDSC were very similar 
(Table S9), but only when the intercept of the LDSC was constrained, which requires the strong assumption of no 
overlapping samples, and only when LD scores were calculated from the actual sample, which is usually not pos-
sible when using GWAS summary statistics. We also observed this phenomenon in our results based on simulated 
data (Supplemental Note 3 and Fig. S9). These observations are in line with the statement in Bulik-Sullivan et al.21 
that standard errors are sacrificed to achieve unbiased genetic correlation and the availability of individual-level 
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genotype data was the most preferable scenario31. Nevertheless, the estimated genetic correlations between SCZ, 
younger AFB and older AFB were consistent using two different approaches, i.e. GREML and LDSC (Table S9).
In summary, this study replicated previously reported evidence for significant genetic overlap between risk of 
SCZ and AFB in women using an independent target sample from the UK Biobank. We further showed that AFB 
in women is genetically heterogeneous (comparing younger to older AFB) and that there is a significant genetic 
correlation between SCZ and AFB. Conducting parallel analyses for AFB in men is of great interest but these 
data are less easily available and AFB has not been recorded for men in the UK Biobank. Our results suggest that 
early, and perhaps also late, age at first birth in women is associated with increased genetic risk for SCZ in the UK 
Biobank samples. These findings contribute new insights into factors contributing to the complex bio-social risk 
architecture underpinning the association between parental age and offspring mental health.
Methods and Materials
Informed consent was obtained from every participant in each study. Research Ethics approval was obtained 
from University of South Australia Human Research Ethics Committee (HREC). All methods were carried out in 
accordance with the relevant guidelines and regulations.
Participants and quality control. Schizophrenia (SCZ) sample. Genome-wide association data were 
available from 18,987 SCZ cases and 22,673 controls from the second phase of the Psychiatric Genomics 
Consortium (PGC)32 with quality control (QC) applied as described in Mehta et al.17. In summary, before 
imputation, PGC group performed a QC for the raw genotypes within each cohort: SNPs with call rate <0.95 
or Hardy-Weinberg equilibrium p-value < 10E-6 in controls or p-value < 10E-10 in cases were excluded. 
Individuals with call rate <0.98 were excluded. Then, the QCed raw genotype data were imputed with IMPUTE2/
SHAPEIT33,34 using the full 1000 Genomes Project dataset35 as the reference set. Post-imputation quality control 
was performed in each cohort as: A best-guess genotype was called if its posterior probability >0.8, otherwise 
treated as missing. SNPs with an imputation r-squared <0.1 or MAF < 0.005, or call rate <0.98 were excluded. 
Out of 39 cohorts, eight cohorts were excluded because the number of SNPs passing the QC process was too small 
and one cohort was excluded because essential covariate information was not available. After the post-imputation 
QC, we combined the genotype data across all cohorts17,32. As in Mehta et al.17, we used HapMap3 SNPs that were 
reliable in estimating (shared) genetic architecture between complex traits36–38. In the combined dataset, SNPs 
with call rate <0.9, individuals with call rate <0.9 were excluded, and one individual in a pair with genomic 
relationship >0.05 was excluded. This less stringent QC for call rate was because SNP and individual QC had 
been already done by the PGC. After this QC, 688,145 SNPs (best-guess genotypes) and 41,630 individuals were 
remained and used to combine with the UK Biobank sample.
UK Biobank sample. In the first version of UK Biobank39 data set, 80,702 female (54,215 with a recode of 
AFB) out of 152,249 genotyped individuals were available from a community sample, in which psychiat-
ric disorders were not enriched, with 72,355,667 imputed SNPs available. Out of all imputed SNPs, 1,242,190 
HapMap3 SNPs were identified, which were filtered through the following QC filtering criteria: SNPs with impu-
tation INFO < 0.617, minor allele frequency (MAF) <0.01, call rate <0.95, and Hardy-Weinberg equilibrium 
P-value < 10–717 were excluded. In addition, ambiguous strand SNPs were excluded. After this QC, 930,841 SNPs 
(best guess genotypes) remained and they were used to merge with the SCZ genotypic data. For individual level 
QC, only Caucasian females were used who clustered within 6 standard deviation from the mean of the EUR 
reference sample40 for the first and second genetic relationship principal components. Individuals were further 
excluded due to call rate <0.95. In addition, one in a pair of individuals was randomly removed if their genomic 
relationship coefficient was more than 0.0517. An important reason for removing closely related individuals was 
to reduce the possibility that the similarity between the phenotypes of those individuals could be caused by 
non-genetic effects (e.g. common environment effects)41. Furthermore, UK Biobank samples were excluded if 
their genomic relationship with any individual in the SCZ or AFB datasets used in Mehta et al.17 was >0.05, in 
order to ensure the independence of the UK Biobank sample. The AFB sample in Mehta et al.17 included 12,247 
genotyped women measured for AFB, who were from four cohorts: Estonia, the Netherlands, Sweden, and the 
United Kingdom. After QC, we used 80,522 individuals (18,957 SCZ cases, 22,673 SCZ controls, and 38,892 UK 
Biobank individuals) and 518,992 SNPs in the main analyses.
Statistical analyses. Estimation of SCZ polygenic risk score (PRS) in UK Biobank sample. We used a GBLUP 
model to generate SCZ PRS for each individual in the UK Biobank sample accounting for the genetic relationship 
between the UK Biobank sample and the SCZ case-control sample. The GBLUP model can be written as
= + +y Xb Zu e,
where y is a vector of phenotypic data (i.e. 1s for SCZ cases, 0s for SCZ controls and missing for UK Biobank 
individuals), b represents vectors of fixed effects including sex, cohort and 20 ancestry principal components 
(PCs)42, u is the vector of SCZ PRS, and e is the vector of residuals. X and Z are design matrices to allocate effects 
to phenotypic data. It is assumed that u is normally distributed as σN G(0, )u
2 , where G is the genomic relation-
ship matrix constructed as described in Yang et al.43 and σu
2 is the additive genetic variance, and e is normally 
distributed as σN I(0, )e
2 , where I is an identify matrix and σe
2 is the residual variance. GBLUP was performed 
using GCTA43 or MTG244,45 so that a subset of u for the UK Biobank sample could be inferred based on the phe-
notypes of the SCZ sample and the genomic relationships between the two data sets. Mean SCZ PRS in the UK 
Biobank individuals grouped by their AFB was estimated to assess the previously reported U-shaped relation-
ship13,17. GBLUP provides more accurate PRS (PRS-GBLUP) under a polygenic genetic architecture than the 
more standard genetic profile score approach18, but for comparison we also calculated PRS by the standard 
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method (PRS-score). To estimate SCZ risk SNP effects, an association test was conducted with PLINK 1.946 using 
the same SCZ GWAS data used in the GBLUP analyses, with phenotypes adjusted for sex, cohort and 20 PCs. 
PRS-scores for individuals in the UK Biobank sample were generated by summing the count of SCZ risk alleles 
weighted by the SNP effects estimated from the association test. In addition to PRS-score, we used the estimated 
SNP effects from the full PGC SCZ GWAS study (33,640 cases and 43,456 controls; publicly available at https://
www.med.unc.edu/pgc/)32 to calculate a further profile risk score in the UK Biobank sample (PRS-scorePGC). 
However, we cannot exclude the possibility of sample overlap or relatedness between the UK Biobank and full 
PGC SCZ data, because we only have a permission to access to the genotypes of 30 cohorts out of 52. Note that we 
used all of the SNPs across the genome (after QC) to calculate SCZ PRS for the UK biobank sample.
Linear prediction. It is of interest to replicate the findings from the epidemiological observation13 that maternal 
ages are associated with SCZ risk in offspring, using the novel design consisting of general community sample 
(UK Biobank) measured for AFB and SCZ PRS. Any significant association between AFB and SCZ PRS from 
a linear prediction gives evidence that the U-shape relationship between maternal ages and risk in offspring 
(observed in McGrath et al.13) can be explained by genetic factors. Using 2,894,688 records from the National 
Danish Registry, McGrath et al.13 reported a U-shaped relationship between risk of SCZ in children and maternal 
age at birth. The resulting equation from the U-shaped relationship (z = 2.7214 − 0.1105X + 0.0018X2) can be 
applied to data of age at first birth of women to generate predictors of risk of SCZ in their children17. We did not 
consider the second model in Mehta et al.17 that was adjusted for partner’s ages because the model was shown 
to be over-corrected17. We calculated the response variable (z) in the UK Biobank sample from the recorded 
age at first birth (X) and this was used as the y-variable in analyses regressing on either PRS-GBLUP, PRS-score 
or PRS-scorePGC and including age at interview, assessment center at which participant consented, genotype 
batch, year of birth and the first 20 PCs as covariates. Socioeconomic status (i.e. education and income level)47 or 
smoking and alcohol drinker status were additionally used to adjust the response variable in sensitivity analyses 
(Fig. S1). Linear models were applied to the group with the full range of AFB records, the subgroup with AFB 
younger than 26 years (<26), and the subgroup with AFB at or older than 26 (≥26), respectively, where the value 
of 26 is the mean of AFB in the UK Biobank sample. From the model, the coefficient of determination (R2) and 
P-value against the null hypothesis (i.e. SCZ PRS of women is not a predictor of AFB) were estimated.
Genomic residual maximum likelihood (GREML). Since previous studies13,17 found that younger and older AFB 
have reciprocal relationship with risk of SCZ (i.e. a U-shaped relationship), it is of interest to test if AFB in women 
is a genetically heterogeneous trait, for instance by estimating the genetic correlation between younger and older 
AFB groups. If the genetic correlation is significantly different from 1, it would imply that the causal variants and/
or their effect sizes differ between younger and older AFB. Moreover, it would be interesting to estimate genetic 
correlations between SCZ case-control data and younger or older AFB groups. The UK Biobank data were divided 
into two groups by younger (<26) and older AFB (≥26). Then, three-variate linear mixed model analysis was 
conducted to estimate genetic variance and covariance between SCZ case-control data, and younger and older 
AFB groups. The model can be written as
= + +
= + + <
= + + ≥
y X b Z g e
y X b Z g e
y X b Z g e
for SCZ sample
for UK Biobank sample with AFB 26
for UK Biobank sample with AFB 26
1 1 1 1 1 1
2 2 2 2 2 2
3 3 3 3 3 3
where y are three column vectors of phenotypic observations (one for each data set or group, i.e. SCZ case-control 
data set, UK Biobank AFB < 26 and UK Biobank AFB ≥ 26). For SCZ case-control data, pre-adjusted pheno-
types corrected for sex, cohort and 20 PCs were used. For the UK Biobank sample, the AFB phenotypes were 
pre-adjusted for sex, age at interview, year of birth, assessment center, genotype batch and 20 PCs. Again, other 
possible confounding factors such as socioeconomic status, and smoking and alcohol drinker status were addi-
tionally controlled in sensitivity analyses to check if the estimates were substantially changed. The GREML anal-
yses were conducted with GCTA43 or MTG244,45 to estimate pairwise genetic correlations among the three data 
sets; SCZ data, and younger AFB and older AFB. We tested if the genetic correlation between SCZ and younger or 
older AFB was significantly different from zero. We also tested if genetic correlation between younger and older 
AFB was significantly different from 1 to assess heterogeneity between the two groups48. We used a Wald test to 
obtain p-values for the test.
References
 1. de Kluiver, H., Buizer-Voskamp, J. E., Dolan, C. V. & Boomsma, D. I. Paternal age and psychiatric disorders: A review. American 
Journal of Medical Genetics Part B: Neuropsychiatric Genetics (2016).
 2. Frans, E. M., Lichtenstein, P., Hultman, C. M. & Kuja-Halkola, R. Age at fatherhood: heritability and associations with psychiatric 
disorders. Psychological Medicine 1–8 (2016).
 3. Mok, P. L. H., Antonsen, S., Pedersen, C. B. & Webb, R. T. Younger or older parental age and risk of suicidality, premature death, 
psychiatric illness, and criminality in offspring. Journal of Affective Disorders 208, 130–138 (2016).
 4. Bulik-Sullivan, B. et al. An Atlas of Genetic Correlations across Human Diseases and Traits. Natrure Genetics 47, 1236–1241 (2015).
 5. Grattan, R. E. et al. Paternal and maternal ages have contrasting associations with self-reported schizophrenia liability. Schizophrenia 
Research 169, 308–312 (2015).
 6. Pearlson, G. D. Etiologic, phenomenologic, and endophenotypic overlap of schizophrenia and bipolar disorder. Annual Review of 
Clinical Psychology 11, 251–281 (2015).
 7. Chang, Z. et al. Maternal age at childbirth and risk for ADHD in offspring: A population-based cohort study. International Journal 
of Epidemiology 43, 1815–1824 (2014).
www.nature.com/scientificreports/
8SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
 8. D’Onofrio, B. M. et al. Paternal age at childbearing and offspring psychiatric and academic morbidity. JAMA Psychiatry 71, 432–8 
(2014).
 9. Malaspina, D., Harlap, S., Fennig, S. & Al, E. Advancing paternal age and the risk of schizophrenia. Archives of General Psychiatry 58, 
361–367 (2001).
 10. Zammit, S. et al. Paternal age and risk for schizophrenia. British Journal of Psychiatry 183, 405–408 (2003).
 11. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia that overlaps with 
bipolar disorder. Natrue 100, 130–134 (2009).
 12. Lopez-Castroman, J. et al. Differences in maternal and paternal age between Schizophrenia and other psychiatric disorders. 
Schizophrenia Research 116, 184–190 (2010).
 13. McGrath, J. J. et al. A comprehensive assessment of parental age and psychiatric disorders. JAMA Psychiatry 71, 301–9 (2014).
 14. Jaffe, A. E., Eaton, W. W., Straub, R. E., Marenco, S. & Weinberger, D. R. Paternal age, de novo mutations and schizophrenia. 
Molecular Psychiatry 19, 274–275 (2014).
 15. Petersen, L., Mortensen, P. B. & Pedersen, C. B. Paternal age at birth of first child and risk of schizophrenia. The American Journal of 
Psychiatry 168, 82–8 (2011).
 16. Pedersen, C. B., McGrath, J., Mortensen, P. B. & Petersen, L. The importance of father’s age to schizophrenia risk. Molecular 
Psychiatry, 530–532 (2014).
 17. Mehta, D. et al. Evidence for genetic overlap between schizophrenia and age at first birth in women. JAMA Psychiatry 73, 497–505 
(2016).
 18. Wray, N. R. et al. Research Review: Polygenic methods and their application to psychiatric traits. Journal of Child Psychology and 
Psychiatry and Allied Disciplines 55, 1068–1087 (2014).
 19. Lesthaeghe, R. J. The unfolding story of the second demographic transition. Population and Development Review 36, 211–251 (2010).
 20. Lee, S. H., Weerasinghe, W. M. S. P. & van der Werf, J. H. J. Genotype-environment interaction on human cognitive function 
conditioned on the status of breastfeeding and maternal smoking around birth. Scientific Reports 7, 6087 (2017).
 21. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. 
Nature Genetics 47, 291–295 (2015).
 22. Frans, E. M. et al. Autism Risk Across Generations: A Population Based Study of Advancing Grandpaternal and Paternal Age. JAMA 
Psychiatry (Chicago, Ill.) 70, 516–521 (2013).
 23. Hultman, C. M., Sandin, S., Levine, S. Z., Lichtenstein, P. & Reichenberg, A. Advancing paternal age and risk of autism: new evidence 
from a population-based study and a meta-analysis of epidemiological studies. Molecular Psychiatry 16, 1203–1212 (2011).
 24. Kong, A. et al. Rate of de novo mutations and the importance of father’s age to disease risk. Nature 488, 471–5 (2012).
 25. Crow, J. F. The high spontaneous mutation rate: Is it a health risk? Proceedings of the National Academy of Sciences 94, 8380–8386 
(1997).
 26. Haldane, J. B. S. The mutation rate of the gene for haemophilia, and its segregation ratios in males and females. Annals of Eugenics 
13, 262–271 (1947).
 27. Vogel, F. & Rathenberg, R. Spontaneous Mutation in Man. In Advances in Human Genetics (eds Harris, H. & Hirschhorn, K.) 
223–318 (Springer US, Boston, MA, 1975).
 28. Crow, J. F. The origins, patterns and implications of human spontaneous mutation. Nature Reviews Genetics 1, 40–47 (2000).
 29. Gratten, J. et al. Risk of psychiatric illness from advanced paternal age is not predominantly from de novo mutations. Nature Genetics 
48, 718–724 (2016).
 30. Chen, G.-B. et al. Across-cohort QC analyses of genome-wide association study summary statistics from complex traits. European 
Journal of Human Genetics 25, 137–146 (2017).
 31. Ni, G., Moser, G., Wray, N. R. & Lee, S. H. Estimation of genetic correlation using linkage disequilibrium score regression and 
genomic restricted maximum likelihood. American Journal of Human Genetics 102, 1185–1194 (2018).
 32. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated 
genetic loci. Nature 511, 421–427 (2014).
 33. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. G3 (Bethesda, Md.) 1, 457–70 (2011).
 34. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. Nature Methods 9, 179–81 
(2012).
 35. McVean, G. A. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).
 36. Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics 45, 1–26 (2013).
 37. Lee, S. H. et al. Estimation of SNP heritability from dense genotype data. American Journal of Human Genetics 93, 1151–1155 (2013).
 38. Tropf, F. C. et al. Human fertility, molecular genetics, and natural selection in modern societies. PLoS One 10, 1–14 (2015).
 39. Collins, R. What makes UK Biobank special? The Lancet 379, 1173–1174 (2012).
 40. The Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).
 41. Yang, J. et al. Common SNPs explain a large proportion of heritability for human height. Natrue Genetics 42, 565–569 (2010).
 42. Lee, S. H. et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nature Genetics 
44, 247–250 (2012).
 43. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A tool for genome-wide complex trait analysis. American Journal of 
Human Genetics 88, 76–82 (2011).
 44. Lee, S. H. & van der Werf, J. MTG2: An efficient algorithm for multivariate linear mixed model analysis based on genomic 
information. Bioinformatics 32, 1420–1422 (2016).
 45. Maier, R. et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder and 
major depression disorder. American Journal of Human Genetics 96, 283–294 (2015).
 46. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4 (2015).
 47. Boivin, J. et al. Associations between maternal older age, family environment and parent and child wellbeing in families using 
assisted reproductive techniques to conceive. Social Science and Medicine 68, 1948–1955 (2009).
 48. Falconer, D. S. & Mackay, T. F. C. Introduction to Quantitative Genetics. (Longmans Green, Harlow, Essex, UK, 1996).
Acknowledgements
This research is supported by the Australian National Health and Medical Research Council (1080157, 1087889, 
1103418, 1127440), and the Australian Research Council (DP160102126, FT160100229). This research has 
been conducted using the UK Biobank Resource. UK Biobank (http://www.ukbiobank.ac.uk) Research Ethics 
Committee (REC) approval number is 11/NW/0382. Our reference number approved by UK Biobank is 14575.
Author Contributions
S.H.L. conceived the idea and directed the study. G.N. and S.H.L. performed the analyses. N.R.W. and J.G. 
provided critical feedback and key elements in interpreting the results. S.H.L., N.R.W., G.N. and J.G. drafted the 
manuscript. All authors contributed to editing and approval of the final manuscript.
www.nature.com/scientificreports/
9SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28160-z.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
www.nature.com/scientificreports/
1 0SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
Consortia
Schizophrenia Working Group of the Psychiatric Genomics Consortium
Stephan Ripke5,6, Benjamin M. Neale5,6,7,8, Aiden Corvin9, James T. R. Walters10, Kai-How 
Farh5, Peter A. Holmans10,11, Phil Lee5,6,8, Brendan Bulik-Sullivan5,6, David A. Collier12,13, 
Hailiang Huang5,7, Tune H. Pers7,14,15, Ingrid Agartz16,17,18, Esben Agerbo19,20,21, Margot 
Albus22, Madeline Alexander23, Farooq Amin24,25, Silviu A. Bacanu26, Martin Begemann27, 
Richard A. Belliveau6, Judit Bene28,29, Sarah E. Bergen6,30, Elizabeth Bevilacqua6, Tim B. 
Bigdeli26, Donald W. Black31, Richard Bruggeman32, Nancy G. Buccola33, Randy L. 
Buckner34,35,36, William Byerley37, Wiepke Cahn38, Guiqing Cai39,40, Dominique Campion41,  
Rita M. Cantor42, Vaughan J. Carr43,44, Noa Carrera10, Stanley V. Catts43,45, Kimberly D. 
Chambert6, Raymond C. K. Chan46, Ronald Y. L. Chen47, Eric Y. H. Chen47,48, Wei Cheng49,  
Eric F. C. Cheung50, Siow Ann Chong51, C. Robert Cloninger52, David Cohen53, Nadine Cohen54, 
Paul Cormican9, Nick Craddock10,11, James J. Crowley55, David Curtis56,57, Michael Davidson58, 
Kenneth L. Davis40, Franziska Degenhardt59,60, Jurgen Del Favero61, Ditte Demontis21,62,63, 
Dimitris Dikeos64, Timothy Dinan65, Srdjan Djurovic18,66, Gary Donohoe9,67, Elodie Drapeau40, 
Jubao Duan68,69, Frank Dudbridge70, Naser Durmishi71, Peter Eichhammer72, Johan 
Eriksson73,74,75, Valentina Escott-Price10, Laurent Essioux76, Ayman H. Fanous77,78,79,80, 
Martilias S. Farrell55, Josef Frank81, Lude Franke82, Robert Freedman83, Nelson B. Freimer84, 
Marion Friedl85, Joseph I. Friedman40, Menachem Fromer5,6,8,86, Giulio Genovese6, Lyudmila 
Georgieva10, Ina Giegling85,87, Paola Giusti-Rodríguez55, Stephanie Godard88, Jacqueline I. 
Goldstein5,7, Vera Golimbet89, Srihari Gopal90, Lieuwe de Haan91, Christian Hammer27, Marian 
L. Hamshere10, Mark Hansen92, Thomas Hansen21,93, Vahram Haroutunian40,94,95, Annette M. 
Hartmann85, Frans A. Henskens43,96,97, Stefan Herms59,60,98, Joel N. Hirschhorn7,15,99, Per 
Hoffmann59,60,98, Andrea Hofman59,60, Mads V. Hollegaard100, David M. Hougaard100, Masashi 
Ikeda101, Inge Joa102, Antonio Juliá103, René S. Kahn38, Luba Kalaydjieva104,105, Sena 
Karachanak-Yankova106, Juha Karjalainen82, David Kavanagh10, Matthew C. Keller107, James L. 
Kennedy108,109,110, Andrey Khrunin111, Yunjung Kim55, Janis Klovins112, James A. Knowles113, 
Bettina Konte85, Vaidutis Kucinskas114, Zita Ausrele Kucinskiene114, Hana Kuzelova-
Ptackova115, Anna K. Kähler30, Claudine Laurent23,116, Jimmy Lee Chee Keong51,117, Sophie E. 
Legge10, Bernard Lerer118, Miaoxin Li47,48,119, Tao Li120, Kung-Yee Liang121, Jeffrey 
Lieberman122, Svetlana Limborska111, Carmel M. Loughland43,123, Jan Lubinski124, Jouko 
Lönnqvist125, Milan Macek115, Patrik K. E. Magnusson30, Brion S. Maher126, Wolfgang Maier127, 
Jacques Mallet128, Sara Marsal103, Manuel Mattheisen21,62,63,129, Morten Mattingsdal18,130, 
Robert W. McCarley131,132, Colm McDonald133, Andrew M. McIntosh134,135, Sandra Meier81, 
Carin J. Meijer91, Bela Melegh28,29, Ingrid Melle18,136, Raquelle I. Mesholam-Gately131,137, 
Andres Metspalu138, Patricia T. Michie43,139, Lili Milani138, Vihra Milanova140, Younes Mokrab12, 
Derek W. Morris9,67, Ole Mors21,62,141, Kieran C. Murphy142, Robin M. Murray143, Inez Myin-
Germeys144, Bertram Müller-Myhsok145,146,147, Mari Nelis138, Igor Nenadic148, Deborah A. 
Nertney149, Gerald Nestadt150, Kristin K. Nicodemus151, Liene Nikitina-Zake112, Laura 
Nisenbaum152, Annelie Nordin153, Eadbhard O’Callaghan154, Colm O’Dushlaine6, F. Anthony 
O’Neill155, Sang-Yun Oh156, Ann Olincy83, Line Olsen21,93, Jim Van Os144,157, Christos 
Pantelis43,158, George N. Papadimitriou64, Sergi Papiol27, Elena Parkhomenko40, Michele T. 
Pato113, Tiina Paunio159,160, Milica Pejovic-Milovancevic161, Diana O. Perkins162, Olli 
Pietiläinen160,163, Jonathan Pimm57, Andrew J. Pocklington10, John Powell143, Alkes Price7,164, 
Ann E. Pulver150, Shaun M. Purcell86, Digby Quested165, Henrik B. Rasmussen21,93, Abraham 
Reichenberg40, Mark A. Reimers166, Alexander L. Richards10, Joshua L. Roffman34,36, Panos 
Roussos86,167, Douglas M. Ruderfer10,86, Veikko Salomaa75, Alan R. Sanders68,69, Ulrich 
Schall43,123, Christian R. Schubert168, Thomas G. Schulze81,169, Sibylle G. Schwab170, Edward M. 
Scolnick6, Rodney J. Scott43,171,172, Larry J. Seidman131,137, Jianxin Shi173, Engilbert 
Sigurdsson174, Teimuraz Silagadze175, Jeremy M. Silverman40,176, Kang Sim51, Petr 
Slominsky111, Jordan W. Smoller6,8, Hon-Cheong So47, Chris C. A. Spencer177, Eli A. Stahl7,86, 
Hreinn Stefansson178, Stacy Steinberg178, Elisabeth Stogmann179, Richard E. Straub180, Eric 
Strengman38,181, Jana Strohmaier81, T. Scott Stroup122, Mythily Subramaniam51, Jaana 
Suvisaari125, Dragan M. Svrakic52, Jin P. Szatkiewicz55, Erik Söderman16, Srinivas 
Thirumalai182, Draga Toncheva106, Sarah Tosato183, Juha Veijola184,185, John Waddington186, 
Dermot Walsh187, Dai Wang90, Qiang Wang120, Bradley T. Webb26, Mark Weiser58,  
Dieter B. Wildenauer188, Nigel M. Williams10, Stephanie Williams55, Stephanie H. Witt81,  
www.nature.com/scientificreports/
1 1SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
Aaron R. Wolen166, Emily H. M. Wong47, Brandon K. Wormley26, Hualin Simon Xi189, Clement 
C. Zai108,109, Xuebin Zheng190, Fritz Zimprich179, Kari Stefansson178, Peter M. Visscher3, Rolf 
Adolfsson153, Ole A. Andreassen18,136, Douglas H. R. Blackwood135, Elvira Bramon191, Joseph 
D. Buxbaum39,40,94,192, Anders D. Børglum21,62,63,141, Sven Cichon59,60,98,193, Ariel Darvasi194, 
Enrico Domenici195, Hannelore Ehrenreich27, Tõnu Esko7,15,99,138, Pablo V. Gejman68,69, Michael 
Gill9, Hugh Gurling57, Christina M. Hultman30, Nakao Iwata101, Assen V. Jablensky43,105,188,196, 
Erik G. Jönsson16,18, Kenneth S. Kendler197, George Kirov10, Jo Knight108,109,110, Todd 
Lencz198,199,200, Douglas F. Levinson23, Qingqin S. Li90, Jianjun Liu190,201, Anil K. 
Malhotra198,199,200, Steven A. McCarroll6,99, Andrew McQuillin57, Jennifer L. Moran6, Preben B. 
Mortensen19,20,21, Bryan J. Mowry86,202, Markus M. Nöthen59,60, Roel A. Ophoff38,42,84, Michael 
J. Owen10,11, Aarno Palotie6,8,163, Carlos N. Pato113, Tracey L. Petryshen6,131,203, Danielle 
Posthuma204,205,206, Marcella Rietschel81, Brien P. Riley197, Dan Rujescu85,87, Pak C. 
Sham47,48,119, Pamela Sklar86,94,167, David St. Clair207, Daniel R. Weinberger180,208, Jens R. 
Wendland168, Thomas Werge21,93,209, Mark J. Daly5,6,7, Patrick F. Sullivan30,55,162 & Michael C. 
O’Donovan10,11
5Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA. 
6Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 02142, 
USA. 7Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 
02142, USA. 8Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, 
Massachusetts, 02114, USA. 9Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College 
Dublin, Dublin, 8, Ireland. 10MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological 
Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK. 11National Centre 
for Mental Health, Cardiff University, Cardiff, CF24 4HQ, UK. 12Eli Lilly and Company Limited, Erl Wood Manor, 
Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. 13Social, Genetic and Developmental Psychiatry Centre, 
Institute of Psychiatry, King’s College London, London, SE5 8AF, UK. 14Center for Biological Sequence Analysis, 
Department of Systems Biology, Technical University of Denmark, Lyngby, DK-2800, Denmark. 15Division of 
Endocrinology and Center for Basic and Translational Obesity Research, Boston Children’s Hospital, Boston, 
Massachusetts, 02115, USA. 16Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, SE, 
17176, Stockholm, Sweden. 17Department of Psychiatry, Diakonhjemmet Hospital, 0319, Oslo, Norway. 
18NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, 0424, Oslo, 
Norway. 19Centre for Integrative Register-based Research, CIRRAU, Aarhus University, DK, 8210, Aarhus, Denmark. 
20National Centre for Register-based Research, AarhusUniversity, DK, 8210, Aarhus, Denmark. 21The Lundbeck 
Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark. 22State Mental Hospital, 
85540, Haar, Germany. 23Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, 
California, 94305, USA. 24Department of Psychiatry and Behavioral Sciences, Atlanta Veterans Affairs Medical 
Center, Atlanta, Georgia, 30033, USA. 25Department of Psychiatry and Behavioral Sciences, Emory University, 
Atlanta, Georgia, 30322, USA. 26Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, 
Virginia Commonwealth University, Richmond, Virginia, 23298, USA. 27Clinical Neuroscience, Max Planck Institute 
of Experimental Medicine, Goettingen, 37075, Germany. 28Department of Medical Genetics, University of Pécs, Pécs, 
H-7624, Hungary. 29Szentagothai Research Center, University of Pécs, Pécs, H-7624, Hungary. 30Department of 
Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE-17177, Sweden. 31Department of 
Psychiatry, University of Iowa Carver College of Medicine, Iowa City, Iowa, 52242, USA. 32University Medical Center 
Groningen, Department of Psychiatry, University of Groningen, Groningen, NL-9700, RB, The Netherlands. 33School 
of Nursing, Louisiana State University Health Sciences Center, New Orleans, Louisiana, 70112, USA. 34Athinoula A 
Martinos Center, Massachusetts General Hospital, Boston, Massachusetts, 02129, USA. 35Center for Brain Science, 
Harvard University, Cambridge, Massachusetts, 02138, USA. 36Department of Psychiatry, Massachusetts General 
Hospital, Boston, Massachusetts, 02114, USA. 37Department of Psychiatry, University of California at San Francisco, 
San Francisco, California, 94143, USA. 38University Medical Center Utrecht, Department of Psychiatry, Rudolf 
Magnus Institute of Neuroscience, 3584, Utrecht, The Netherlands. 39Department of Human Genetics, Icahn School 
of Medicine at Mount Sinai, New York, New York, 10029, USA. 40Department of Psychiatry, Icahn School of Medicine 
at Mount Sinai, New York, New York, 10029, USA. 41Centre Hospitalier du Rouvray and INSERM U1079 Faculty of 
Medicine, 76301, Rouen, France. 42Department of Human Genetics, David Geffen School of Medicine, University of 
California, Los Angeles, California, 90095, USA. 43Schizophrenia Research Institute, Sydney, NSW, 2010, Australia. 
44School of Psychiatry, University of New South Wales, Sydney, NSW, 2031, Australia. 45Royal Brisbane and Women’s 
Hospital, University of Queensland, Brisbane, St Lucia, QLD, 4072, Australia. 46Institute of Psychology, Chinese 
Academy of Science, Beijing, 100101, China. 47Department of Psychiatry, Li Ka Shing Faculty of Medicine, The 
University of Hong Kong, Hong Kong, China. 48State Key Laboratory for Brain and Cognitive Sciences, Li Ka Shing 
Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 49Department of Computer Science, University 
of North Carolina, Chapel Hill, North Carolina, 27514, USA. 50Castle Peak Hospital, Hong Kong, China. 51Institute of 
Mental Health, Singapore, 539747, Singapore. 52Department of Psychiatry, Washington University, St. Louis, 
Missouri, 63110, USA. 53Department of Child and Adolescent Psychiatry, Assistance Publique Hopitaux de Paris, 
Pierre and Marie Curie Faculty of Medicine and Institute for Intelligent Systems and Robotics, Paris, 75013, France. 
54Blue Note Biosciences, Princeton, New Jersey, 08540, USA. 55Department of Genetics, University of North Carolina, 
Chapel Hill, North Carolina, 27599-7264, USA. 56Department of Psychological Medicine, Queen Mary University of 
London, London, E1 1BB, UK. 57Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, 
www.nature.com/scientificreports/
1 2SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
London, WC1E6JJ, UK. 58Sheba Medical Center, Tel Hashomer, 52621, Israel. 59Department of Genomics, Life and 
Brain Center, D-53127, Bonn, Germany. 60Institute of Human Genetics, University of Bonn, D-53127, Bonn, Germany. 
61Applied Molecular Genomics Unit, VIB Department of Molecular Genetics, University of Antwerp, B-2610, Antwerp, 
Belgium. 62Centre for Integrative Sequencing, iSEQ, Aarhus University, DK-8000, Aarhus C, Denmark. 63Department 
of Biomedicine, , Aarhus University, DK-8000, Aarhus C, Denmark. 64First Department of Psychiatry, University of 
Athens Medical School, Athens, 11528, Greece. 65Department of Psychiatry, , University College Cork, Co Cork, 
Ireland. 66Department of Medical Genetics, Oslo University Hospital, 0424, Oslo, Norway. 67Cognitive Genetics and 
Therapy Group, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Co 
Galway, Ireland. 68Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois, 
60637, USA. 69Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, 
Illinois, 60201, USA. 70Department of Non-Communicable Disease Epidemiology, London School of Hygiene and 
Tropical Medicine, London, WC1E 7HT, UK. 71Department of Child and Adolescent Psychiatry, University Clinic of 
Psychiatry, Skopje, 1000, Macedonia. 72Department of Psychiatry, University of Regensburg, 93053, Regensburg, 
Germany. 73Department of General Practice, Helsinki University Central Hospital, University of Helsinki, Po Box 20, 
Tukholmankatu 8 B, FI-00014, Helsinki, Finland. 74Folkhälsan Research Center, Biomedicum Helsinki 1, 
Haartmaninkatu 8, FI-00290, Helsinki, Finland. 75National Institute for Health and Welfare, PO Box 30, FI-00271, 
Helsinki, Finland. 76Translational Technologies and Bioinformatics, Pharma Research and Early Development, F 
Hoffman-La Roche, CH-4070, Basel, Switzerland. 77Department of Psychiatry, Georgetown University School of 
Medicine, Washington, DC, 20057, USA. 78Department of Psychiatry, Keck School of Medicine of the University of 
Southern California, Los Angeles, California, 90033, USA. 79Department of Psychiatry, Virginia Commonwealth 
University School of Medicine, Richmond, Virginia, 23298, USA. 80Mental Health Service Line, Washington VA 
Medical Center, Washington, DC, 20422, USA. 81Department of Genetic Epidemiology in Psychiatry, Central Institute 
of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, D-68159, Mannheim, Germany. 
82Department of Genetics, University of Groningen, University Medical Centre Groningen, 9700 RB, Groningen, The 
Netherlands. 83Department of Psychiatry, University of Colorado Denver, Aurora, Colorado, 80045, USA. 84Center for 
Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los 
Angeles, California, 90095, USA. 85Department of Psychiatry, University of Halle, 06112, Halle, Germany. 86Division 
of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, 
New York, 10029, USA. 87Department of Psychiatry, University of Munich, 80336, Munich, Germany. 88Departments 
of Psychiatry and Human and Molecular Genetics, INSERM, Institut de Myologie, Hôpital de la Pitiè-Salpêtrière, 
Paris, 75013, France. 89Mental Health Research Centre, Russian Academy of Medical Sciences, 115522, Moscow, 
Russia. 90Neuroscience Therapeutic Area, Janssen Research and Development, Raritan, New Jersey, 08869, USA. 
91Academic Medical Centre University of Amsterdam, Department of Psychiatry, 1105 AZ, Amsterdam, The 
Netherlands. 92Illumina, La Jolla, California, California, 92122, USA. 93Institute of Biological Psychiatry, Mental Health 
Centre Sct Hans, Mental Health Services Copenhagen, Copenhagen, DK-4000, Denmark. 94Friedman Brain Institute, 
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA. 95J J Peters VA Medical Center, Bronx, 
New York, New York, 10468, USA. 96Priority Research Centre for Health Behaviour, University of Newcastle, 
Newcastle, NSW, 2308, Australia. 97School of Electrical Engineering and Computer Science, University of Newcastle, 
Newcastle, NSW, 2308, Australia. 98Division of Medical Genetics, Department of Biomedicine, University of Basel, 
Basel, CH-4058, Switzerland. 99Department of Genetics, Harvard Medical School, Boston, Massachusetts, 
Massachusetts, 02115, USA. 100Section of Neonatal Screening and Hormones, Department of Clinical Biochemistry, 
Immunology and Genetics, Statens Serum Institut, Copenhagen, DK-2300, Denmark. 101Department of Psychiatry, 
Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan. 102Regional Centre for Clinical Research 
in Psychosis, Department of Psychiatry, Stavanger University Hospital, 4011, Stavanger, Norway. 103Rheumatology 
Research Group, Vall d’Hebron Research Institute, Barcelona, 08035, Spain. 104Centre for Medical Research, The 
University of Western Australia, Perth, WA6009, Australia. 105The Perkins Institute for Medical Research, The 
University of Western Australia, Perth, WA6009, Australia. 106Department of Medical Genetics, Medical University, 
Sofia, 1431, Bulgaria. 107Department of Psychology, University of Colorado Boulder, Boulder, Colorado, 80309, USA. 
108Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, M5T 
1R8, Canada. 109Department of Psychiatry, University of Toronto, Toronto, Ontario, M5T 1R8, Canada. 110Institute of 
Medical Science, University of Toronto, Toronto, Ontario, M5S 1A8, Canada. 111Institute of Molecular Genetics, 
Russian Academy of Sciences, Moscow, 123182, Russia. 112Latvian Biomedical Research and Study Centre, Riga, LV-
1067, Latvia. 113Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of Medicine at University 
of Southern California, Los Angeles, California, 90089, USA. 114Faculty of Medicine, Vilnius University, LT-01513, 
Vilnius, Lithuania. 115Department of Biology and Medical Genetics, 2nd Faculty of Medicine and University Hospital 
Motol, 150 06, Prague, Czech Republic. 116Department of Child and Adolescent Psychiatry, Pierre and Marie Curie 
Faculty of Medicine, Paris, 75013, France. 117Duke-NUS Graduate Medical School, Singapore, 169857, Singapore. 
118Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem, 91120, Israel. 119Centre for 
Genomic Sciences, The University of Hong Kong, Hong Kong, China. 120Mental Health Centre and Psychiatric 
Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 121Department of 
Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, 21205, USA. 
122Department of Psychiatry, Columbia University, New York, New York, 10032, USA. 123Priority Centre for 
Translational Neuroscience and Mental Health, University of Newcastle, Newcastle, NSW2300, Australia. 
124Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in 
Szczecin, 70-453, Szczecin, Poland. 125Department of Mental Health and Substance Abuse Services, National 
Institute for Health and Welfare, PO BOX30, FI-00271, Helsinki, Finland. 126Department of Mental Health, Bloomberg 
School of Public Health, Johns Hopkins University, Baltimore, Maryland, 21205, USA. 127Department of Psychiatry, 
University of Bonn, D-53127, Bonn, Germany. 128Centre National de la Recherche Scientifique, Laboratoire de 
www.nature.com/scientificreports/
13SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
Génétique Moléculaire de la Neurotransmission et des Processus Neurodégénératifs, Hôpital de la Pitié Salpêtrière, 
75013, Paris, France. 129Department of Genomics Mathematics, University of Bonn, D-53127, Bonn, Germany. 
130Research Unit, Sørlandet Hospital, 4604, Kristiansand, Norway. 131Department of Psychiatry, Harvard Medical 
School, Boston, Massachusetts, 02115, USA. 132VA Boston Health Care System, Brockton, Massachusetts, 02301, 
USA. 133Department of Psychiatry, National University of Ireland Galway, Co Galway, Ireland. 134Centre for Cognitive 
Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH16 4SB, UK. 135Division of Psychiatry, 
University of Edinburgh, Edinburgh, EH16 4SB, UK. 136Division of Mental Health and Addiction, Oslo University 
Hospital, 0424, Oslo, Norway. 137Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel 
Deaconess Medical Center, Boston, Massachusetts, 02114, USA. 138Estonian Genome Center, University of Tartu, 
Tartu, 50090, Estonia. 139School of Psychology, University of Newcastle, Newcastle, NSW, 2308, Australia. 140First 
Psychiatric Clinic, Medical University, Sofia, 1431, Bulgaria. 141Department P, Aarhus University Hospital, DK-8240, 
Risskov, Denmark. 142Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 143King’s 
College London, London, SE5 8AF, UK. 144Maastricht University Medical Centre, South Limburg Mental Health 
Research and Teaching Network, EURON, 6229 HX, Maastricht, The Netherlands. 145Institute of Translational 
Medicine, University of Liverpool, Liverpool, L69 3BX, UK. 146Max Planck Institute of Psychiatry, 80336, Munich, 
Germany. 147Munich Cluster for SystemsNeurology (SyNergy), 80336, Munich, Germany. 148Department of 
Psychiatry and Psychotherapy, Jena University Hospital, 07743, Jena, Germany. 149Department of Psychiatry, 
Queensland Brain Institute and Queensland Centre for Mental Health Research, University of Queensland, Brisbane, 
Queensland, St Lucia QLD, 4072, Australia. 150Department of Psychiatry and Behavioral Sciences, Johns Hopkins 
University School of Medicine, Baltimore, Maryland, 21205, USA. 151Department of Psychiatry, Trinity College 
Dublin, Dublin 2, Ireland. 152Eli Lilly and Company, Lilly Corporate Center, Indianapolis, 46285, Indiana, USA. 
153Department of Clinical Sciences, Psychiatry, Umeå University, SE-901 87, Umeå, Sweden. 154DETECT Early 
Intervention Service for Psychosis, Blackrock, Co Dublin, Ireland. 155Centre for Public Health, Institute of Clinical 
Sciences, Queen’s University Belfast, Belfast, BT12 6AB, UK. 156Lawrence Berkeley National Laboratory, University 
of California at Berkeley, Berkeley, California, 94720, USA. 157Institute of Psychiatry, Kings College London, London, 
SE5 8AF, UK. 158Melbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Melbourne, Vic, 
3053, Australia. 159Department of Psychiatry, University of Helsinki, PO Box 590, FI-00029, HUS, Helsinki, Finland. 
160Public Health Genomics Unit, National Institute for Health and Welfare, PO BOX 30, FI-00271, Helsinki, Finland. 
161Medical Faculty, University of Belgrade, 11000, Belgrade, Serbia. 162Department of Psychiatry, University of North 
Carolina, Chapel Hill, North Carolina, 27599-7160, USA. 163Institute for Molecular Medicine Finland, FIMM, University 
of Helsinki, PO Box 20, FI-00014, Helsinki, Finland. 164Department of Epidemiology, Harvard School of Public Health, 
Boston, Massachusetts, 02115, USA. 165Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK. 
166Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia, 
23298, USA. 167Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, 
USA. 168PharmaTherapeutics Clinical Research, Pfizer Worldwide Research and Development, Cambridge, 
Massachusetts, 02139, USA. 169Department of Psychiatry and Psychotherapy, University of Gottingen, 37073, 
Göttingen, Germany. 170Psychiatry and Psychotherapy Clinic, University of Erlangen, 91054, Erlangen, Germany. 
171Hunter New England Health Service, Newcastle, NSW, 2308, Australia. 172School of Biomedical Sciences, 
University of Newcastle, Newcastle, NSW, 2308, Australia. 173Division of Cancer Epidemiology and Genetics, 
National Cancer Institute, Bethesda, Maryland, 20892, USA. 174University of Iceland, Landspitali, National University 
Hospital, 101, Reykjavik, Iceland. 175Department of Psychiatry and Drug Addiction, Tbilisi State Medical University 
(TSMU), N33, 0177, Tbilisi, Georgia. 176Research and Development, Bronx Veterans Affairs Medical Center, New York, 
New York, 10468, USA. 177Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK. 178deCODE Genetics, 
101, Reykjavik, Iceland. 179Department of Clinical Neurology, Medical University of Vienna, 1090, Wien, Austria. 
180Lieber Institute for Brain Development, Baltimore, Maryland, 21205, USA. 181Department of Medical Genetics, 
University Medical Centre Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands. 182Berkshire Healthcare 
NHS Foundation Trust, Bracknell, RG12 1BQ, UK. 183Section of Psychiatry, University of Verona, 37134, Verona, Italy. 
184Department of Psychiatry, University of Oulu, PO Box 5000, Oulu, 90014, Finland. 185University Hospital of Oulu, 
PO Box 20, 90029, OYS, Oulu, Finland. 186Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 
Dublin 2, Ireland. 187Health Research Board, Dublin 2, Ireland. 188School of Psychiatry and Clinical Neurosciences, The 
University of Western Australia, Perth, WA6009, Australia. 189Computational Sciences CoE, Pfizer Worldwide 
Research and Development, Cambridge, Massachusetts, 02139, USA. 190Human Genetics, Genome Institute of 
Singapore, A STAR, Singapore, 138672, Singapore. 191University College London, London, WC1E 6BT, UK. 
192Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA. 
193Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, 52428, Juelich, Germany. 194Department 
of Genetics, The Hebrew University of Jerusalem, 91905, Jerusalem, Israel. 195Neuroscience Discovery and 
Translational Area, Pharma Research and Early Development, F Hoffman-La Roche, CH-4070, Basel, Switzerland. 
196Centre for Clinical Research in Neuropsychiatry, School of Psychiatry and Clinical Neurosciences, The University of 
Western Australia, Medical Research Foundation Building, Perth, WA6000, Australia. 197Virginia Institute for 
Psychiatric and Behavioral Genetics, Departments of Psychiatry and Human and Molecular Genetics, Virginia 
Commonwealth University, Richmond, Virginia, 23298, USA. 198The Feinstein Institute for Medical Research, 
Manhasset, New York, 11030, USA. 199The Hofstra NS-LIJ School of Medicine, Hempstead, New York, 11549, USA. 
200The Zucker Hillside Hospital, Glen Oaks, New York, 11004, USA. 201Saw Swee Hock School of Public Health, 
National University of Singapore, Singapore, 117597, Singapore. 202Queensland Centre for Mental Health Research, 
University of Queensland, Brisbane, 4076, Queensland, Australia. 203Center for Human Genetic Research and 
Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA. 204Department of 
Child and Adolescent Psychiatry, Erasmus University Medical Centre, Rotterdam, 3000, The Netherlands. 
205Department of Complex Trait Genetics, Neuroscience Campus Amsterdam, VU University Medical Center 
www.nature.com/scientificreports/
1 4SCIENTIfIC RepoRts |  (2018) 8:10168  | DOI:10.1038/s41598-018-28160-z
Amsterdam, Amsterdam, 1081, The Netherlands. 206Department of Functional Genomics, Center for Neurogenomics 
and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, 1081, The Netherlands. 
207University of Aberdeen, Institute of Medical Sciences, Aberdeen, AB25 2ZD, UK. 208Departments of Psychiatry, 
Neurology, Neuroscience and Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, 
21205, USA. 209Department of Clinical Medicine, University of Copenhagen, Copenhagen, 2200, Denmark. 
